Rationale for IL-15 superagonists in cancer immunotherapy

Expert Opin Biol Ther. 2020 Jul;20(7):705-709. doi: 10.1080/14712598.2020.1738379. Epub 2020 Mar 11.

Authors

Karin M Knudson¹, James W Hodge¹, Jeffrey Schlom¹, Sofia R Gameiro¹

Affiliation

¹ Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD, USA.

PMID: 32159390
DOI: 10.1080/14712598.2020.1738379

No abstract available

Keywords: CD8 T cells; IL-15 superagonist; NK cells; immune activation.

Publication types

Editorial
Research Support, N.I.H., Intramural